Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775396 | 0.81 | LMNA (0.45) | LPLLIPGPRKCZCYP1A2CYP3A4 | |
| SCHEMBL31620789 | 0.81 | LMNA (0.45) | LPLLIPGPRKCZCYP1A2CYP3A4 | |
| SCHEMBL17485941 | 0.80 | CYP11B1 (0.39) | PRKCZCYP11B2CYP11B1ADRA2AADRA2B | |
| SCHEMBL29586872 | 0.79 | LPL (0.44) | LPLLIPGCYP1A2CYP3A4ANPEP | |
| SCHEMBL476862 | 0.79 | LPL (0.44) | LPLLIPGCYP1A2CYP3A4ANPEP | |
| SCHEMBL15272484 | 0.78 | EGFR (0.35) | LPLLIPGEGFR | |
| SCHEMBL25608331 | 0.74 | LPL (0.34) | LPLLIPGCYP3A4KDM4E | |
| SCHEMBL2027186 | 0.74 | LPL (0.48) | LPLLIPGANPEPLAP3 | |
| SCHEMBL476863 | 0.73 | LPL (0.36) | LPLLIPGEGFR | |
| SCHEMBL20017911 | 0.73 | CYP1A2 (0.47) | LPLLIPGCYP1A2ANPEPLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404249-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2025-09-02 | — | — | US | disclosed |
| EP-3802495-B1 | 4-(2-((2-CHLOROQUINOLIN-4-YL)AMINO)ETHYL)BENZENESULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | C&C RES LAB (KR) | 2025-07-02 | — | — | EP | disclosed |
| US-20250109135-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | INNOVO THERAPEUTICS INC. (KR) | 2025-04-03 | — | — | US | disclosed |
| EP-4461726-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | Innovo Therapeutics Inc. (KR) | 2024-11-13 | — | — | EP | disclosed |
| CN-112204010-B | Heterocyclic derivatives and uses thereof | C&C新药研究所 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023132606-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | 주식회사 이노보테라퓨틱스 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023132606-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | 주식회사 이노보테라퓨틱스 | 2023-07-13 | — | — | WO | disclosed |
| US-20230056324-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2023-02-23 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-04 | — | — | US | disclosed |
| EP-2055702-A1 | Anthracene-based compound and organic light emitting device employing the same | Samsung Electronics Co., Ltd. (KR) | 2009-05-06 | — | — | EP | disclosed |
| US-20090108746-A1 | Anthracene-based compound and organic light emitting device employing the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2009-04-30 | — | — | US | disclosed |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-2041139-A2 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| EP-1860098-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | NEURO3D (FR) | 2006-06-15 | — | — | US | disclosed |
| EP-1556055-A2 | USE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE IN THERAPY | NEURO3D (FR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041258-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES | NEURO3D (FR) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213520-B2 | Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors | CDK9, CDK19, CDK8 | LPL 4824/4885LIPG 4695/4885PRKCZ 677/4885 |
| US-20230056324-A1 | METAL COMPLEXES | MCU, IMMT, SOD1 | LPL 4205/4885LIPG 3736/4885PRKCZ 4148/4885 |
| US-20250109135-A1 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | CASP1, CASP8, CASP2 | LPL 2337/4885LIPG 2901/4885PRKCZ 3132/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | LPL 3598/4885LIPG 2592/4885PRKCZ 241/4885 |
| US-12404249-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, IRF3 | LPL 3989/4885LIPG 2463/4885PRKCZ 1638/4885 |
| US-20060128695-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses | PDE7A, PDE4A, PDE4B | LPL 2446/4885LIPG 3209/4885PRKCZ 424/4885 |
| US-20090108746-A1 | Anthracene-based compound and organic light emitting device employing the same | CCNL2, CRY2, ATXN2L | LPL 2662/4885LIPG 4265/4885PRKCZ 4592/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | LPL 4432/4885LIPG 2582/4885PRKCZ 4464/4885 |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP11, MMP3 | LPL 4805/4885LIPG 4844/4885PRKCZ 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.